Scope and Patent Landscape for US Patent 10,272,083 (BTK Inhibitor 100 mg BID Formula (II) in CLL/SLL and MCL)
US 10,272,083 is a US-method patent that claims a specific oral BTK inhibitor dosing regimen (100 mg twice daily) using a chemical definition by “Formula (II),” applied to two oncology indications: chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and mantle cell lymphoma (MCL). The claims are broad in disease coverage (including biomarker- and phenotype-defined CLL subgroups) and in combination therapy scaffolding (anti-CD20 antibodies plus a large enumerated list of anticoagulants/antiplatelets). Practically, this places a licensing and litigation risk on any US commercialization of an oral BTK inhibitor that (i) falls within Formula (II), (ii) is administered at 100 mg BID, and (iii) is used for the claimed clinical populations and time windows, including in combination regimens.
However, claim breadth is constrained by the need to meet all structural and regimen elements simultaneously: (a) BTK inhibitor must be a compound of Formula (II) (or permitted salt/solvate/hydrate), (b) dosing is fixed at 100 mg twice daily, and (c) multiple dependent claims add time windows (about 14/28/56 days), specific CLL definitions, MCL immune cell changes, and specified add-on classes.
What does US Patent 10,272,083 claim: method of treating CLL/SLL or MCL with a BTK inhibitor at 100 mg twice daily?
Core independent claim structure (Claim 1 for CLL/SLL; Claim 8 for MCL):
- Route: oral administration
- Dose: 100 mg twice daily
- Active: a BTK inhibitor defined by Formula (II) (or pharmaceutically acceptable salt/solvate/hydrate)
- Patient population: human subject with CLL or SLL (Claim 1) or MCL (Claim 8)
Claim 1 (CLL/SLL) scope
Claim 1 is a classic “use/administration” method claim:
- Treating CLL or SLL
- With an oral BTK inhibitor defined by Formula (II)
- At 100 mg twice daily
It is not limited to:
- line of therapy
- refractory status
- whether therapy is monotherapy vs combination (combination appears in dependent claims)
Claim 8 (MCL) scope
Claim 8 mirrors Claim 1 but swaps indication:
- Treating MCL
- With oral BTK inhibitor (Formula (II)) at 100 mg twice daily
How broad is the chemical and drug-form definition: what does “Formula (II) BTK inhibitor” cover in practice?
The claims repeatedly require the BTK inhibitor to be a compound of Formula (II). The patent text you provided does not include the structural definition itself (the actual chemistry of Formula (II)), so the effective scope turns on what Formula (II) encompasses.
Within the provided claim set, Formula (II) is the gating element for infringement. Even perfect matching of dose and indication does not matter unless:
- the accused BTK inhibitor falls within Formula (II), or
- the accused product is a permitted pharmaceutically acceptable salt/solvate/hydrate of a Formula (II) compound.
Form rights expressly built into the claims
The claims cover:
- free base/form
- pharmaceutically acceptable salts
- solvates
- hydrates
This prevents easy design-around through polymorph or salt selection (at least as long as those variants remain “pharmaceutically acceptable” and fall within the Formula (II) family).
What patient subclasses and disease characteristics are covered for CLL in US 10,272,083?
Claim 4 narrows Claim 2 (Formula (II) + dosing) with a CLL subtype list that is unusually explicit and inclusive. It includes:
- IgVH mutation negative CLL
- ZAP-70 positive CLL
- ZAP-70 methylated at CpG3 CLL
- CD38 positive CLL
- CLL with 17p13.1 (17p) deletion
- CLL with 11q22.3 (11q) deletion
- CLL in a human sensitive to platelet-mediated thrombosis
- CLL in a human presently suffering from platelet-mediated thrombosis
- CLL in a human previously suffering from platelet-mediated thrombosis
- combinations thereof
Scope impact
This language matters in practice because CLL subtyping can be used in:
- clinical trial arms
- labeling claims (if reflected)
- post-hoc subgroup claims in promotional materials
- payer/access rationales
If a BTK inhibitor product is used in the US in any of those populations, dependent claim 4 can be triggered (subject to meeting the dose and Formula (II) elements).
What treatment durations are claimed: does the patent specify 14, 28, or 56 days?
Yes. Claim 3 limits the administration period:
- about 14 days
- about 28 days
- about 56 days
This is tied to Claim 2 (Formula (II) plus salt/form) in the provided text:
- Claim 3 is a dependent limitation: “wherein the BTK inhibitor is administered… for a period selected from…” those time windows.
Scope impact
- If an accused regimen does not match these duration windows, Claim 3 is not met.
- Independent claims (1 and 8) do not explicitly require a 14/28/56-day duration; they only require treating the diseases with 100 mg BID. Duration becomes central mainly for the dependent claims.
How does the patent expand scope via combination therapy: anti-CD20 antibodies and anticoagulants/antiplatelets?
Two dependent claim “combination layers” materially expand coverage.
Anti-CD20 antibody add-on (Claims 5 and 12)
For CLL/SLL (Claim 5) and MCL (Claim 12), the method includes administering a therapeutically effective dose of an anti-CD20 antibody chosen from:
- rituximab
- obinutuzumab
- ofatumumab
- veltuzumab
- tositumomab
- ibritumomab
- fragments, derivatives, conjugates, variants, radioisotope-labeled complexes
- and biosimilars
Scope impact: The list is broad across anti-CD20 products and includes “fragments/variants” plus biosimilars, making it difficult to avoid by selecting a different CD20 agent or using biosimilar equivalents.
Anticoagulant/antiplatelet add-on (Claims 6-7 and 13-14)
For CLL/SLL (Claim 6 plus Claim 7) and MCL (Claim 13 plus Claim 14), the combination includes administering a therapeutically effective dose of an anticoagulant or antiplatelet selected from a very large enumerated list, including widely used agents such as:
- apixaban, rivaroxaban, dabigatran etexilate, edoxaban
- warfarin and warfarin sodium
- clopidogrel (and bisulfate)
- aspirin and aspirin with extended-release dipyridamole
- heparin and low-molecular-weight heparins (enoxaparin, dalteparin, nadroparin, tinzaparin, etc.)
- ticagrelor, prasugrel, cilostazol, ticlopidine
- GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)
- and a long tail of additional anticoagulants/antiplatelets
Scope impact:
- The claims are compatible with standard-of-care thromboembolism prophylaxis and management in an oncology setting.
- The breadth makes “we did not co-prescribe X” a weaker defense because many commonly used agents are explicitly named.
Does the patent also claim mechanistic biomarkers for MCL patients (monocytes/NK cells)?
Yes. Claim 10 adds a measurable biological effect:
- “Mantle Cell Lymphoma (MCL) increases monocytes and NK cells in peripheral blood after treatment with Formula (II)”
- with treatment period selected from about 14, about 28, about 56 days
Scope impact
This is a dependent limitation that can:
- support a unique “biomarker response” infringement theory for method claims
- strengthen the patent’s defensibility against obviousness-type arguments (depending on how the specification frames it)
Still, enforcement would require proving the accused therapy meets all claim elements, including the dosing and Formula (II) identity.
What formulations are claimed: free base vs salt/solvate/hydrate?
The claims explicitly cover free form and pharmaceutically acceptable salts.
- Claims 17-20 add explicit “free form” and “salt” dependent alternatives:
- Claim 17: free form administered
- Claim 18: pharmaceutically acceptable salt administered
- Claim 19: free form in MCL context
- Claim 20: salt in MCL context
Solvates and hydrates are referenced in the independent claims and in the manner of defining Formula (II) compounds as “salt, hydrate, or solvate.” Dependent claims you provided specifically highlight free form and salt, but the overall claim set includes hydrate/solvate coverage via the independent claims.
How would US patent validity and infringement analysis typically be mapped for a Formula-defined BTK inhibitor like this?
Even without the exact structural Formula (II), the claim architecture implies a standard infringement map for method claims of BTK inhibitors:
Infringement checklist by claim tier
For independent Claim 1 (CLL/SLL):
- Accused product is an oral BTK inhibitor that is a Formula (II) compound (or permitted variant).
- Accused regimen uses 100 mg BID.
- Treatment is for CLL or SLL in a human.
For independent Claim 8 (MCL):
- Formula (II) compound
- Oral 100 mg BID
- Treatment for MCL
For dependent claims:
- add-on 14/28/56-day duration (Claim 3)
- add CLL subtype/biomarker/thrombosis sensitivity elements (Claim 4)
- add anti-CD20 agent (Claim 5)
- add anticoagulant/antiplatelet agent (Claims 6-7)
- add anti-CD20 for MCL (Claim 12)
- add anticoagulant/antiplatelet for MCL (Claims 13-14)
- add MCL-specific monocyte/NK response after treatment time window (Claim 10)
- add free-form vs salt (Claims 17-20)
What does this imply about “generic entry risks” for 100 mg twice-daily BTK inhibitors used in CLL/SLL/MCL?
This claim set is the kind that can create post-approval exposure not only for generics but also for:
- label and off-label use patterns
- physician protocols in CLL/SLL and MCL
- combination therapy pathways
Key risk drivers
- Dose lock-in: 100 mg BID is a bright-line parameter. If a competitor uses a different dose, dependent claim scope shrinks, but independent claims still require 100 mg BID.
- Indication alignment: enforcement is strongest where treatment is clearly directed to CLL/SLL or MCL.
- Combination layering: anti-CD20 and anticoagulant/antiplatelet dependencies widen exposure to real-world co-therapy patterns.
- Patient subgroup language: CLL biomarker-thrombosis sensitivity wording can make it harder to segregate patient classes to avoid method-claim coverage.
How strong is the patent estate likely to be relative to other BTK inhibitor patents?
Based on claim style alone, US 10,272,083 is a narrow-to-medium chemical gate (Formula (II)) with broad clinical and regimen permutations (indications, subtypes, duration, and combination payloads). In most BTK portfolios, the estate strength typically comes from:
- multiple method-of-use claims
- multiple formulation claims
- and multiple overlapping dosing or combination claims
This patent is best categorized as a dose-and-indication method claim with extensive dependent combination coverage. The enforceability and practical leverage depends on whether Formula (II) corresponds to a specific commercial BTK inhibitor (and whether competitors try to design around the chemical definition rather than the dosing and use).
Patent landscape comparison: which BTK inhibitors typically align with “100 mg twice daily” claims?
The claim set does not name the molecule in the text you supplied. But as an analytic construct for landscape mapping, the key search should be:
- identify which US BTK inhibitor products are dosed at 100 mg BID and used in CLL/SLL and/or MCL
- then test whether those products contain a core chemical structure matching “Formula (II”
Because “Formula (II)” is the infringement hinge, the landscape question becomes: does any marketed or pipeline BTK inhibitor correspond structurally to Formula (II)? If yes, dose and indication create a direct enforcement pathway.
(Without the actual Formula (II) structure or the patent’s specification/claims chemistry section, no reliable molecule mapping can be made from the provided excerpt.)
Orange Book, FDA, Paragraph IV and biosimilar risks: what can be inferred from these claims?
- This is a method of treatment patent, which can be listed in the Orange Book only if it qualifies for listing under 21 USC §355(b)(1). Method claims are often listed as “use” patents.
- For a BTK inhibitor small molecule, biosimilar risk is generally irrelevant; biosimilar risk attaches to biologics such as the anti-CD20 antibodies named in the dependent claims. Here, the biologics are referenced as combinations, but the BTK inhibitor itself is not a biologic.
- Paragraph IV risks attach to generic/similar small molecules that rely on Abbreviated New Drug Applications (ANDAs). If the BTK inhibitor is being genericized, method claims listed for the branded product can drive litigation.
These inferences depend on the actual Orange Book listing status and the FDA marketing authorization for the relevant BTK inhibitor product, which is not included in the provided information.
Key takeaways
- US 10,272,083 is a BTK inhibitor method-of-treatment patent with a hard dosing requirement (100 mg twice daily) and a hard chemical definition gate (Formula (II)).
- It covers two oncology indications: CLL/SLL (Claim 1) and MCL (Claim 8).
- Claim 4 expands CLL scope into specific biomarker and deletion subgroups and platelet-mediated thrombosis sensitivity/occurrence.
- Dependent claims materially broaden real-world regimen coverage through:
- anti-CD20 antibody combinations (Claims 5 and 12)
- anticoagulant/antiplatelet combinations across a long enumerated list (Claims 6-7 and 13-14)
- Dependent claim 3 and claim 10 define time-window elements (about 14/28/56 days) including an MCL peripheral blood monocyte/NK cell response concept.
- For competitive risk, the decisive infringement question is structural identity with Formula (II) plus use at 100 mg BID for the specified diseases, including combination therapy patterns.
FAQs
1) What elements must be proven to establish infringement of Claim 1 (CLL/SLL)?
Oral administration of a BTK inhibitor that is a compound of Formula (II) (or permitted variants), at 100 mg twice daily, to a human to treat CLL or SLL.
2) Does Claim 3 limit the patent to 14/28/56-day dosing only?
Claim 3 is a dependent limitation tied to Claim 2 (Formula (II)). It limits the duration for that dependent claim, but Claim 1 itself is not textually limited to those durations in the excerpt provided.
3) Are anti-CD20 combinations mandatory to fall within the patent?
No. Anti-CD20 antibodies appear in dependent claims (Claim 5 for CLL/SLL; Claim 12 for MCL). Independent coverage exists without the combination in the excerpt.
4) Can substitution with a different anticoagulant avoid the anticoagulant-dependent claims?
Avoidance would require using an anticoagulant/antiplatelet not in the enumerated list in the dependent claims, while still meeting the other claim elements.
5) Is biosimilar risk relevant because anti-CD20 antibodies are named?
Biosimilar risk typically attaches to the biologics (anti-CD20 antibodies) themselves, but these are in combination within dependent claims. The BTK inhibitor coverage is for a small molecule defined by Formula (II).
References
- US Patent 10,272,083, “Method of treating chronic lymphocytic leukemia and mantle cell lymphoma,” claims as provided by user input.
